http://pharmacology.miningco.com/library/98news/bln1111a.htm
Angiogenesis Inhibitor Combrestatin, by
OXiGENE, Begins PHASE I Clinical
Trials 11/11/98
| Press Release | Angiogenesis Featured Articles | More
Info | Questions or Comments? Post Them on the
Board!
Angiogenesis Inhibitors in Clinical Trials - List of
Drugs and Contact Information
Press Release: Tumor Vascular Targeting Agent
Attacks Cancer-Specific Blood Vessels Formed by
Angiogenesis
Boston, Massachusetts, November 11, 1998 -
Addressing the ABN AMRO Health Care Conference in
New York, Björn Nordenvall, M.D., Ph.D., President
and Chief Executive Officer of OXiGENE,
(Nasdaq:OXGN; SSE:OXGN) announced today that the
Company has begun treating the first patient in a U.S.
Phase I clinical trial of Combretastatin A-4 Prodrug for
the treatment of solid tumors. In addition, the Company
announced plans to initiate a second Phase I study with
Combretastatin in the U.S. later this year and the British
charity, Cancer Research Campaign, is commencing a
third Phase I study in the U.K. OXiGENE’s clinical
trials of Combretastatin will evaluate three different
dosing regimens, as well as the safety, pharmacokinetics,
reduction of tumor blood flow and maximum tolerated
dose of Combretastatin in humans. Combretastatin is
believed to be the first in a new class of drugs known as
tumor vascular targeting agents, which selectively targets
and destroys cancer-specific blood vessels formed by
angiogenesis.
"More than 90 percent of all cancers are solid tumors,
and most rely on the blood supply to survive and grow,"
said Scot Remick, M.D., Program Leader,
Developmental Therapeutics Division of Hematology
and Oncology, Ireland Cancer Center at University
Hospitals of Cleveland and Associate Professor of
Medicine at Case Western Reserve University. "In
preclinical studies, Combretastatin demonstrated
potency as a stand-alone therapy, and increased potency
in combination with other agents in destroying tumor
vasculature. These trials represent the first opportunity
to assess the use of this promising new compound in
humans."
"The development of Combretastatin is in line with the
Company’s overall strategy to discover new products
that will enhance the effectiveness of conventional
cancer therapies," said Dr. Nordenvall. "Initial data
from the Phase I trials will determine the safety of
Combretastatin as a stand-alone therapy and will frame
the design of future trials which will evaluate
Combretastatin in combination with other cancer
treatments."
Tumor vascular targeting and angiogenesis inhibition are
related but distinct cancer therapies, which radically
depart from conventional approaches to treating cancer.
Certain new drugs in this class of compounds target a
tumor’s life support system, the network of newly
emerging blood vessels, while leaving blood vessels
associated with normal tissue unaffected. A process
called angiogenesis, which is the growth of new blood
vessels from previously existing ones, forms the
tumor-specific blood vessels. Combretastatin differs
from anti-angiogenesis drugs in that Combretastatin
destroys existing blood vessels in tumors, whereas
anti-angiogenesis drugs inhibit the growth of new blood
vessels in tumors.
Combretastatin is being developed as a drug that could
potentially be used in combination with chemotherapy
and radiation to enhance the effectiveness of these
traditional cancer treatments. In animal studies,
Combretastatin was shown to selectively attack and
destroy existing tumor vasculature, creating a rapid and
irreversible shutdown of the tumors’ blood vessels. In
one such study, published in Cancer Research, v.
57:1829 (May 1997) researchers found that a single
dose of Combretastatin reduced tumor blood flow in
mice by 93 percent. Twenty-four hours after injection
with Combretastatin, 95 percent of the cancer cells were
dead as a result of being deprived of oxygen and
nutrients.
OXiGENE is an international biopharmaceutical
company developing a diverse portfolio of innovative
products to combat cancer and other major diseases. The
Company’s mission is to develop new therapeutics that
will enhance the effectiveness of traditional cancer
treatments. OXiGENE has several product candidates in
clinical development, including a second-generation
DNA repair inhibitor Neu-Sensamide‘, in Phase III
clinical trials in patients with non-small cell lung cancer
and a Phase I study in patients with glioblastoma; a
third-generation DNA repair inhibitor Declopramide
(previously OXi-104), in Phase I studies in patients with
advanced stage cancers; Combretastatin A-4 Prodrug, a
tumor vascular targeting agent for the treatment of solid
tumors, in Phase I studies in patients with advanced
stage cancers; and Cordycepin, in Phase I/II studies in
patients with TdT-positive leukemia.
SOURCE: OXiGENE
See also Angiogenesis Inhibitors in Clinical Trials -
List of Drugs and Contact Information
Return to top
For more information, try searching this web site
(search box on upper left of each page). If you still
need more info concerning individual drugs, it can
usually be obtained from the Specific Drug Search
Sites listed in our Pharmacology Links Library. Drug
Manufacturer's Web Sites are also a good source,
especially for newer drugs when other information is
less readily available. If you've tried and still can't find
the info you need, try posting your question on the
Pharmacology Bulletin Board. I monitor the BB
regularly, and reply to many questions. But if you have a
particular interest or expertise, please, feel free to reply
to questions or add your comments or opinions. I regret
that I can't answer specific email questions, although
your comments are always welcome.
Return to Drugs in the News Index
New Drug Approvals Index
Drug Manufacturer's Web Sites
Featured Articles
Return to top
produced/revised/updated: 11/22/98 09:03 AM
Related About.com GuideSites
Anesthesiology
Biology
Dentistry
Dermatology
Family Medicine
Genetics
Internal Medicine
Mental Health Resources
Neurosciences
Nursing
Ophthalmology
Pediatrics
Sports Medicine
Surgery
Veterinary Medicine
Elsewhere on About.com
Today's Top Stories
Stock Quotes
Special Olympics Preview
High-Tech Quilting
JustAbout
Quit Smoking
Graduation
Twisted Travel
Search
This Site About.com
Share This Site With a Friend (enter their email address below):
Top of Page
Sun, Jun 27, 1999
Mary Ann Elchisak - your About.com
Guide to:
Pharmacology
You are
here:
Home > Health/Fitness > Medicine > Pharmacology >
Guide Extra
Content:
Welcome | Netlinks | Articles | Guide Bio | Search | Related
TalkAbout:
Forums | Chat | Events | Newsletter | Feedback | Share This
Site | Join
ShopAbout:
Books | ShopCenter | Videos | Yellow Pages
Angiogenesis Inhibitor Combrestatin, by
OXiGENE, Begins PHASE I Clinical
Trials 11/11/98
| Press Release | Angiogenesis Featured Articles | More
Info | Questions or Comments? Post Them on the
Board!
Angiogenesis Inhibitors in Clinical Trials - List of
Drugs and Contact Information
Press Release: Tumor Vascular Targeting Agent
Attacks Cancer-Specific Blood Vessels Formed by
Angiogenesis
Boston, Massachusetts, November 11, 1998 -
Addressing the ABN AMRO Health Care Conference in
New York, Björn Nordenvall, M.D., Ph.D., President
and Chief Executive Officer of OXiGENE,
(Nasdaq:OXGN; SSE:OXGN) announced today that the
Company has begun treating the first patient in a U.S.
Phase I clinical trial of Combretastatin A-4 Prodrug for
the treatment of solid tumors. In addition, the Company
announced plans to initiate a second Phase I study with
Combretastatin in the U.S. later this year and the British
charity, Cancer Research Campaign, is commencing a
third Phase I study in the U.K. OXiGENE’s clinical
trials of Combretastatin will evaluate three different
dosing regimens, as well as the safety, pharmacokinetics,
reduction of tumor blood flow and maximum tolerated
dose of Combretastatin in humans. Combretastatin is
believed to be the first in a new class of drugs known as
tumor vascular targeting agents, which selectively targets
and destroys cancer-specific blood vessels formed by
angiogenesis.
"More than 90 percent of all cancers are solid tumors,
and most rely on the blood supply to survive and grow,"
said Scot Remick, M.D., Program Leader,
Developmental Therapeutics Division of Hematology
and Oncology, Ireland Cancer Center at University
Hospitals of Cleveland and Associate Professor of
Medicine at Case Western Reserve University. "In
preclinical studies, Combretastatin demonstrated
potency as a stand-alone therapy, and increased potency
in combination with other agents in destroying tumor
vasculature. These trials represent the first opportunity
to assess the use of this promising new compound in
humans."
"The development of Combretastatin is in line with the
Company’s overall strategy to discover new products
that will enhance the effectiveness of conventional
cancer therapies," said Dr. Nordenvall. "Initial data
from the Phase I trials will determine the safety of
Combretastatin as a stand-alone therapy and will frame
the design of future trials which will evaluate
Combretastatin in combination with other cancer
treatments."
Tumor vascular targeting and angiogenesis inhibition are
related but distinct cancer therapies, which radically
depart from conventional approaches to treating cancer.
Certain new drugs in this class of compounds target a
tumor’s life support system, the network of newly
emerging blood vessels, while leaving blood vessels
associated with normal tissue unaffected. A process
called angiogenesis, which is the growth of new blood
vessels from previously existing ones, forms the
tumor-specific blood vessels. Combretastatin differs
from anti-angiogenesis drugs in that Combretastatin
destroys existing blood vessels in tumors, whereas
anti-angiogenesis drugs inhibit the growth of new blood
vessels in tumors.
Combretastatin is being developed as a drug that could
potentially be used in combination with chemotherapy
and radiation to enhance the effectiveness of these
traditional cancer treatments. In animal studies,
Combretastatin was shown to selectively attack and
destroy existing tumor vasculature, creating a rapid and
irreversible shutdown of the tumors’ blood vessels. In
one such study, published in Cancer Research, v.
57:1829 (May 1997) researchers found that a single
dose of Combretastatin reduced tumor blood flow in
mice by 93 percent. Twenty-four hours after injection
with Combretastatin, 95 percent of the cancer cells were
dead as a result of being deprived of oxygen and
nutrients.
OXiGENE is an international biopharmaceutical
company developing a diverse portfolio of innovative
products to combat cancer and other major diseases. The
Company’s mission is to develop new therapeutics that
will enhance the effectiveness of traditional cancer
treatments. OXiGENE has several product candidates in
clinical development, including a second-generation
DNA repair inhibitor Neu-Sensamide‘, in Phase III
clinical trials in patients with non-small cell lung cancer
and a Phase I study in patients with glioblastoma; a
third-generation DNA repair inhibitor Declopramide
(previously OXi-104), in Phase I studies in patients with
advanced stage cancers; Combretastatin A-4 Prodrug, a
tumor vascular targeting agent for the treatment of solid
tumors, in Phase I studies in patients with advanced
stage cancers; and Cordycepin, in Phase I/II studies in
patients with TdT-positive leukemia.
SOURCE: OXiGENE
See also Angiogenesis Inhibitors in Clinical Trials -
List of Drugs and Contact Information
Return to top
For more information, try searching this web site
(search box on upper left of each page). If you still
need more info concerning individual drugs, it can
usually be obtained from the Specific Drug Search
Sites listed in our Pharmacology Links Library. Drug
Manufacturer's Web Sites are also a good source,
especially for newer drugs when other information is
less readily available. If you've tried and still can't find
the info you need, try posting your question on the
Pharmacology Bulletin Board. I monitor the BB
regularly, and reply to many questions. But if you have a
particular interest or expertise, please, feel free to reply
to questions or add your comments or opinions. I regret
that I can't answer specific email questions, although
your comments are always welcome.
Return to Drugs in the News Index
New Drug Approvals Index
Drug Manufacturer's Web Sites
Featured Articles
Return to top
produced/revised/updated: 11/22/98 09:03 AM
Related About.com GuideSites
Anesthesiology
Biology
Dentistry
Dermatology
Family Medicine
Genetics
Internal Medicine
Mental Health Resources
Neurosciences
Nursing
Ophthalmology
Pediatrics
Sports Medicine
Surgery
Veterinary Medicine
Elsewhere on About.com
Today's Top Stories
Stock Quotes
Special Olympics Preview
High-Tech Quilting
JustAbout
Quit Smoking
Graduation
Twisted Travel
Search
This Site About.com
Share This Site With a Friend (enter their email address below):
Top of Page
Sun, Jun 27, 1999
Mary Ann Elchisak - your About.com
Guide to:
Pharmacology
You are
here:
Home > Health/Fitness > Medicine > Pharmacology >
Guide Extra
Content:
Welcome | Netlinks | Articles | Guide Bio | Search | Related
TalkAbout:
Forums | Chat | Events | Newsletter | Feedback | Share This
Site | Join
ShopAbout:
Books | ShopCenter | Videos | Yellow Pages
Angiogenesis Inhibitor Combrestatin, by
OXiGENE, Begins PHASE I Clinical
Trials 11/11/98
| Press Release | Angiogenesis Featured Articles | More
Info | Questions or Comments? Post Them on the
Board!
Angiogenesis Inhibitors in Clinical Trials - List of
Drugs and Contact Information
Press Release: Tumor Vascular Targeting Agent
Attacks Cancer-Specific Blood Vessels Formed by
Angiogenesis
Boston, Massachusetts, November 11, 1998 -
Addressing the ABN AMRO Health Care Conference in
New York, Björn Nordenvall, M.D., Ph.D., President
and Chief Executive Officer of OXiGENE,
(Nasdaq:OXGN; SSE:OXGN) announced today that the
Company has begun treating the first patient in a U.S.
Phase I clinical trial of Combretastatin A-4 Prodrug for
the treatment of solid tumors. In addition, the Company
announced plans to initiate a second Phase I study with
Combretastatin in the U.S. later this year and the British
charity, Cancer Research Campaign, is commencing a
third Phase I study in the U.K. OXiGENE’s clinical
trials of Combretastatin will evaluate three different
dosing regimens, as well as the safety, pharmacokinetics,
reduction of tumor blood flow and maximum tolerated
dose of Combretastatin in humans. Combretastatin is
believed to be the first in a new class of drugs known as
tumor vascular targeting agents, which selectively targets
and destroys cancer-specific blood vessels formed by
angiogenesis.
"More than 90 percent of all cancers are solid tumors,
and most rely on the blood supply to survive and grow,"
said Scot Remick, M.D., Program Leader,
Developmental Therapeutics Division of Hematology
and Oncology, Ireland Cancer Center at University
Hospitals of Cleveland and Associate Professor of
Medicine at Case Western Reserve University. "In
preclinical studies, Combretastatin demonstrated
potency as a stand-alone therapy, and increased potency
in combination with other agents in destroying tumor
vasculature. These trials represent the first opportunity
to assess the use of this promising new compound in
humans."
"The development of Combretastatin is in line with the
Company’s overall strategy to discover new products
that will enhance the effectiveness of conventional
cancer therapies," said Dr. Nordenvall. "Initial data
from the Phase I trials will determine the safety of
Combretastatin as a stand-alone therapy and will frame
the design of future trials which will evaluate
Combretastatin in combination with other cancer
treatments."
Tumor vascular targeting and angiogenesis inhibition are
related but distinct cancer therapies, which radically
depart from conventional approaches to treating cancer.
Certain new drugs in this class of compounds target a
tumor’s life support system, the network of newly
emerging blood vessels, while leaving blood vessels
associated with normal tissue unaffected. A process
called angiogenesis, which is the growth of new blood
vessels from previously existing ones, forms the
tumor-specific blood vessels. Combretastatin differs
from anti-angiogenesis drugs in that Combretastatin
destroys existing blood vessels in tumors, whereas
anti-angiogenesis drugs inhibit the growth of new blood
vessels in tumors.
Combretastatin is being developed as a drug that could
potentially be used in combination with chemotherapy
and radiation to enhance the effectiveness of these
traditional cancer treatments. In animal studies,
Combretastatin was shown to selectively attack and
destroy existing tumor vasculature, creating a rapid and
irreversible shutdown of the tumors’ blood vessels. In
one such study, published in Cancer Research, v.
57:1829 (May 1997) researchers found that a single
dose of Combretastatin reduced tumor blood flow in
mice by 93 percent. Twenty-four hours after injection
with Combretastatin, 95 percent of the cancer cells were
dead as a result of being deprived of oxygen and
nutrients.
OXiGENE is an international biopharmaceutical
company developing a diverse portfolio of innovative
products to combat cancer and other major diseases. The
Company’s mission is to develop new therapeutics that
will enhance the effectiveness of traditional cancer
treatments. OXiGENE has several product candidates in
clinical development, including a second-generation
DNA repair inhibitor Neu-Sensamide‘, in Phase III
clinical trials in patients with non-small cell lung cancer
and a Phase I study in patients with glioblastoma; a
third-generation DNA repair inhibitor Declopramide
(previously OXi-104), in Phase I studies in patients with
advanced stage cancers; Combretastatin A-4 Prodrug, a
tumor vascular targeting agent for the treatment of solid
tumors, in Phase I studies in patients with advanced
stage cancers; and Cordycepin, in Phase I/II studies in
patients with TdT-positive leukemia.
SOURCE: OXiGENE
See also Angiogenesis Inhibitors in Clinical Trials -
List of Drugs and Contact Information
Return to top
For more information, try searching this web site
(search box on upper left of each page). If you still
need more info concerning individual drugs, it can
usually be obtained from the Specific Drug Search
Sites listed in our Pharmacology Links Library. Drug
Manufacturer's Web Sites are also a good source,
especially for newer drugs when other information is
less readily available. If you've tried and still can't find
the info you need, try posting your question on the
Pharmacology Bulletin Board. I monitor the BB
regularly, and reply to many questions. But if you have a
particular interest or expertise, please, feel free to reply
to questions or add your comments or opinions. I regret
that I can't answer specific email questions, although
your comments are always welcome.
Return to Drugs in the News Index
New Drug Approvals Index
Drug Manufacturer's Web Sites
Featured Articles
Return to top
produced/revised/updated: 11/22/98 09:03 AM
Related About.com GuideSites
Anesthesiology
Biology
Dentistry
Dermatology
Family Medicine
Genetics
Internal Medicine
Mental Health Resources
Neurosciences
Nursing
Ophthalmology
Pediatrics
Sports Medicine
Surgery
Veterinary Medicine
Elsewhere on About.com
Today's Top Stories
Stock Quotes
Special Olympics Preview
High-Tech Quilting
JustAbout
Quit Smoking
Graduation
Twisted Travel
Search
This Site About.com
Share This Site With a Friend (enter their email address below):
Top of Page
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
